GT Biopharma Inc
Research GT Biopharma Inc (GTBP) on Bullrun: market cap USD 12.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGTBP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.15M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.83M
- Free cash flow-USD 2.47M
Valuation Snapshot
latest market cap is USD 12.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 28.35M | -USD 12.91M | n/a | -6.68 | USD 6.81M | n/a | USD 5.79M |
| FY2024 | USD 0 | -USD 13.16M | -USD 12.90M | n/a | -6.94 | USD 3.95M | USD 0 | -USD 1.67M |
| FY2023 | USD 0 | -USD 7.60M | -USD 8.85M | n/a | -5.64 | USD 1.08M | USD 58.00K | USD 7.48M |
| FY2022 | USD 0 | -USD 20.88M | -USD 15.22M | n/a | -19.66 | USD 5.67M | USD 174.00K | USD 11.73M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 12.15M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.17M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.81M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 28.85M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 97.79M | n/a | n/a | n/a |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GT Biopharma Inc's market cap?
GT Biopharma Inc's market capitalization is USD 12.15M.
What does GT Biopharma Inc do?
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.